New Interleukin Inhibitors May Give Stelara A Run For The Psoriasis Money

Data showing IL-17 blockers Cosentyx and brodalumab beat J&J’s IL-12/23 inhibitor Stelara in psoriasis make a strong impression at the American Academy of Dermatology meeting, but that doesn’t necessarily mean they’ll be preferred.

More from Clinical Trials

More from R&D